AddThis Social Bookmark Button

Tiens Biotech Group (USA), Inc. News

Tiens Biotech Group (USA) Reports First Quarter Results

NEW YORK, May 15 Xinhua-PRNewswire — Tiens Biotech Group (USA), Inc. (the ''Company'' or ''Tiens''), (Amex: TBV), http://www.tiens-bio.com , announced financial results for the first quarter ended March 31, 2008.

Revenue for the first quarter of 2008 was $12.8 million compared to $16.2 million for the first quarter of 2007.

Net income for the first quarter of 2008 was $3.6 million, or $0.05 per share, compared to net income of $6.5 million, or $0.09 per share for the first quarter of 2007.

Revenue by Region

For the first quarter of 2008, revenue in China was $6.1 million compared to $7.2 million for the first quarter of 2007. Sales in China reflect the continued uncertainty regarding the effect of direct selling regulations and the timing of the direct selling license application process and approval. The application of Tianshi Engineering for a direct selling license in China is still pending and until the application is approved, Tianshi Engineering will continue to sell Tiens' products through its branches, affiliated companies and chain stores in China.

For the first quarter of 2008, international revenue was $6.7 million, compared to $9.0 million for the first quarter of 2007.

The change in international sales reflects China's General Administration of Quality Supervision, Inspection and Quarantine's (AQSIQ) ongoing national campaign in China against unsafe food and substandard products. As a result of this campaign by the AQSIQ, there has been a general slow-down and backlog of export clearances for Chinese food products. As a result of these delays, Tiens' international affiliates were not able to purchase sufficient quantities of its products to meet their demand. However, it is important to note that to date, no problems have been identified with any of Tiens' products. The campaign, which began in August 2007, was originally scheduled to finish at the end of 2007, is currently scheduled to continue throughout 2008.

Other Highlights

Cost of sales for the first quarter of 2008 was $4.0 million compared to $4.4 million for the same period in 2007. This decrease was primarily due to the decrease in sales revenue. The decrease in cost of sales was not in line with the decrease in revenue due to increases in the cost of our raw materials, and a strong remenbi compared to the dollar.

Gross profit for the first quarter of 2008 was $8.8 million compared to $11.8 million for the first quarter of 2007. The gross profit margin for the first quarter of 2008 was 68.5%, compared to 72.7% for the first quarter of 2007. The decreases reflect the aforementioned cost of raw materials which increased while the price at which products were sold remained constant.

Selling, general and administrative expenses were $3.2 million for the first quarter of 2008 and 2007. The selling and administrative expenses as a percentage of sales was 25.3% for the first quarter of 2008 compared to 20.1% for the same period in 2007. This increase reflects the fixed costs associated with selling, general and administrative expenses and the decline in revenue.

As of March 31, 2008, Tiens had $82.3 million of retained earnings and total shareholders' equity of $121.0 million.

Jinyuan Li, Chairman, President and CEO of Tiens, said, ''We continue to face the challenges of the current direct selling environment in China and delays in exporting our products internationally. Our high quality products have remained beyond reproach by the national campaign in China to prevent the export of unsafe products. We see future opportunities including the development of new products and enhancing our current manufacturing capabilities as part of our strategic initiatives to best position Tiens for long term domesic and international growth.''

About Tiens Biotech Group (USA), Inc. ( http://www.tiens-bio.com )

Tiens Biotech Group (USA), Inc. (AMEX: TBV) conducts its business operations from Tianjin, People's Republic of China. Tiens primarily engages in the research, development, manufacturing, and marketing of nutrition supplement products, including wellness products and dietary nutrition supplement products, and personal care products.

Tiens derives its revenues principally from product sales to affiliated companies in China and internationally in 52 countries. Since its establishment, Tiens has developed and produced 33 nutrition supplements, which include wellness products and dietary supplements. Tiens develops its products at its own product research and development center, which employs highly qualified professionals in the fields of pharmacology, biology, chemistry and fine chemistry. Tiens has obtained all required certificates and approvals from government regulatory agencies to manufacture and sell its products in China.

In China, Tiens conducts the marketing and sales of its products through its affiliated company, Tianshi Engineering. Tianshi Engineering markets and sells Tiens' products in China through chain stores, domestic affiliated companies, and its 100 branches. Outside of China, Tiens sells its products to affiliated companies in 52 countries who in turn sell through an extensive direct sales force, or multi-level marketing sales force. The Company's direct sales marketing program is subject to governmental regulation in each of these countries.

Certain statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Such forward-looking statements are not necessarily indicative of future financial results, and may involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to: (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) whether the Company continues to experience delays in the export clearance of its products; (v) whether Tianshi Engineering, the Company's affiliate which sells its products in China, obtains a direct selling license in China; and (vi) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at http://www.sec.gov under ''Search for Company Filings.''

—Tables Follow— TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME FOR THE THREE MONTHS ENDED MARCH 31, 2008 AND 2007 2007 2008 As Adjusted (Unaudited) (See Note 1) REVENUE - RELATED PARTIES $ 12,820,821 $ 16,236,789 COST OF SALES - RELATED PARTIES 4,040,060 4,435,599 GROSS PROFIT 8,780,761 11,801,190 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES 3,247,199 3,264,907 INCOME FROM OPERATIONS 5,533,562 8,536,283 (Interest expense) (52,584) (105,222) Interest income 237,332 629,913 Other expense income, net 259,423 (74,479) OTHER EXPENSE INCOME, NET 444,171 450,212 INCOME BEFORE PROVISION FOR INCOME TAXES AND MINORITY INTEREST 5,977,733 8,986,495 PROVISION FOR INCOME TAXES 1,480,394 711,010 INCOME BEFORE MINORITY INTEREST 4,497,339 8,275,485 MINORITY INTEREST 888,437 1,753,218 NET INCOME 3,608,902 6,522,267 OTHER COMPREHENSIVE INCOME Foreign currency translation adjustment 4,423,860 1,389,352 COMPREHENSIVE INCOME $ 8,032,762 $ 7,911,619 EARNINGS PER SHARE, BASIC AND DILUTED $ 0.05 $ 0.09 WEIGHTED AVERAGE NUMBER OF SHARES 71,333,586 71,333,586 TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2008 AND DECEMBER 31, 2007 A S S E T S March 31, December 31, 2008 2007 (unaudited) As Adjusted (See Note 1) CURRENT ASSETS: Cash $ 58,160,829 $ 54,081,848 Accounts receivable, trade - related parties, net of allowance for doubtful accounts of $59,412 and $71,700 as of March 31, 2008 and December 31, 2007, respectively 11,822,927 14,268,229 Accounts receivable, trade - third parties —- 104,398 Inventories 6,649,229 5,949,963 Other receivables 851,436 1,068,343 Other receivables - related parties 12,744,336 13,887,138 Employee advances 118,583 65,901 Prepaid expenses 533,330 623,638 Total current assets 90,880,670 90,049,458 PROPERTY, PLANT AND EQUIPMENT, net 16,135,968 16,071,900 OTHER ASSETS: Construction in progress 46,332,756 39,792,774 Construction deposits 1,036,204 1,089,216 Intangible assets, net 9,576,608 9,246,879 Other assets 5,569,703 5,301,847 Total other assets 62,515,271 55,430,716 Total assets $ 169,531,909 $ 161,552,074 TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2008 AND DECEMBER 31, 2007 L I A B I L I T I E S A N D S H A R E H O L D E R S' E Q U I T Y March 31, December 31, 2008 2007 As Adjusted (Unaudited) (See Note 1) CURRENT LIABILITIES: Accounts payable $ 4,085,944 $ 4,070,906 Advances from customers - related parties 1,772,749 1,700,838 Wages and benefits payable 1,096,302 1,250,685 Other taxes payable 175,324 536,819 Income taxes payable 1,740,778 665,736 Contractor deposits 329,665 595,128 Contractor payables 8,666,740 7,820,285 Other Payables 1,342,448 1,133,539 Other payables - related parties 4,885,515 7,938,205 Dividend payable to minority interest 5,106,666 4,902,629 Current portion of long term debt, related party 2,130,000 2,130,000 Total current liabilities 31,302,131 32,744,760 NON-CURRENT LIABILITIES: Long term debt, net of current portion, related party 4,267,742 4,267,742 Other payables-non-current 560,526 538,130 Deferred income 5098,771 4,895,049 Total non-current liabilities 9,927,039 9,700,921 Total liabilities 41,229,170 42,445,681 MINORITY INTEREST 7,307,647 6,144,063 SHAREHOLDERS' EQUITY: Common stock, $0.001 par value, 250,000,000 shares authorized, 71,333,586 issued and outstanding, respectively 71,334 71,334 Paid-in-capital 8,842,009 8,842,009 Statutory reserves 9,420,783 9,420,783 Retained earnings 82,277,062 78,668,160 Accumulated other comprehensive income 20,383,904 15,590,044 Total shareholders' equity 120,995,092 112,962,330 Total liabilities and shareholders' equity $ 169,531,909 $161,552,074 TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2008 AND 2007 Three months ended March 31 2008 2007 As Adjusted (Unaudited) (See Note 1) CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 3,608,902 $ 6,522,267 Adjustments to reconcile net income to cash provided by (used in) operating activities: Provision for doubtful accounts (12,288) (2,819) Minority interest 888,437 1,753,218 Depreciation 683,155 700,148 Amortization 60,894 58,597 Interest income (53,159) (405,211) (Gain) loss on sale of assets (8,431) — (Increase) decrease in assets: Accounts receivable, trade - related parties (3,914,933) (3,633,193) Accounts receivable, trade - third parties 106,413 — Other receivables 255,386 (16,831) Other receivables - related parties (198,638) 599,858 Inventories (441,968) 653,771 Employee advances (48,871) 18,164 Prepaid expense 112,341 (107,382) Increase (decrease) in liabilities: Accounts payable (169,891) (902,938) Advances from customers - related parties 1,102 (43,110) Wages and benefits payable (200,580) (11,718) Other taxes payable 649,299 398,094 Other payables 158,270 (152,536) Other payables - related parties 125,300 (297,067) Net cash provided by operating activities 1,600,740 5,131,312 CASH FLOWS FROM INVESTING ACTIVITIES: Loan to (from) related parties 1,403,831 (1,032,080) Acquisition of intangible assets — (127,996) Construction deposits 96,237 207,822 Contractor deposits (284,016) — Addition to construction in progress (4,257,203) (5,926,815) Purchase of equipment and automobiles (123,344) (296,416) Net cash used in investing activities (3,164,495) (7,175,485) CASH FLOWS FROM FINANCING ACTIVITIES: Loan from related parties 3,489,184 374,129 Increase in registered share capital — 5,500,010 Payments to minority interest shareholder — (6,676,102) Net cash provided by (used in) financing activities 3,489,184 (801,963) EFFECT OF EXCHANGE RATE CHANGES ON CASH 2,153,552 509,087 INCREASE IN CASH 4,078,981 (2,337,049) CASH, beginning of year 54,081,848 55,214,540 CASH, end of year $ 58,160,829 $ 52,877,491 Supplemental disclosures of cash flow information Cash paid during the year for: Interest (net of amount capitalized) $ — $ — Income taxes $ 455,480 $ 700,941 Note 1.

On December 20, 2007, the Company's subsidiary, Tianshi International Holdings Group Ltd (''Tianshi Holdings''), entered into a Sale and Purchase Agreement with Tianshi International Investment Group Co., Ltd. (''Tianshi Investment''). Pursuant to the Sale and Purchase Agreement, Tianshi Holdings agreed to buy all of the registered share capital of Tianjin Tiens Life Resources Co., Ltd. (''Life Resources'') for $64.2 million. The closing of the transaction was subject to government approval of transfer of all of the share capital of Life Resources to Tianshi Holdings. On March 13, 2008, the Chinese government approved the transfer. As Tianshi Holdings and Life Resources were under common control by Jinyuan Li before the combination, the combination was treated for accounting purposes as a pooling of interests. The balance sheet of the Company at December 31, 2007 and comparative interim financial statements for the corresponding periods of the preceding fiscal year were adjusted as if Life Resources had been combined before January 1, 2007.

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES REVENUE BY REGION Three months ended March 31, 2008 2007 Change China $6,105,779 $7,210,301 -15.3% International $6,715,042 $9,026,488 -25.6% Total $12,820,821 $16,236,789 -21.0% For more information, please contact: Investor Relations Tiens Biotech Group (USA), Inc. Tel: +86-22-8213-7915 Fax: +86-22-8213-7667 Email: investor@tiens-bio.com Web: http://www.tiens-bio.com Carl Hymans G. S. Schwartz & Co. Tel: +1-212-725-4500 Fax: +1-212-725-9188 Email: carlh@schwartz.com

SOURCE Tiens Biotech Group (USA), Inc.

Send this news item to a friend.

Print This Page

Search Our News Using Google Search

Can't find what you want? Try using Google:

Google